BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
CXCL2
,
cell-cell adhesion
,
Ischemia
,
Hippocampus
,
Hematopoietic cell
,
Doxorubicin
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
semaphorins class 4
NextBio Summary
General Info
Curated Studies
Most Correlated Studies
Altered transcriptome in a motor system spared by ALS
Egr2-dependent expression in T cell anergy
Explore Curated Studies Results
Literature
Most Relevant Literature
Reduced expression of semaphorin 4D and plexin-B in breast cancer is associated with poorer prognosi…
The class 4 semaphorin Sema4D promotes the rapid assembly of GABAergic synapses in rodent hippocampu…
Semaphorins: From Angiogenesis to Inflammation in Rheumatoid Arthritis.
The impact of Semaphorin 4C/Plexin-B2 signaling on fear memory via remodeling of neuronal and synapt…
Emerging role of plexins signaling in glioma progression and therapy.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer
VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ